Analyst action$AMRX8:33 AM ET

Oppenheimer initiates Amneal Pharmaceuticals at Outperform, target $27

By BORSA NewsroomPublished Sep 23, 2026, 8:33 AM EDTUpdated Sep 25, 2026, 1:51 PM EDT

Oppenheimer initiated coverage of Amneal Pharmaceuticals (AMRX) with an Outperform rating and a price target of $27. The initiation was announced September 23, 2026.

Sentimentbullish 65

Bullish · 65 of 100

Impact20

low · stays off the top drivers

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerts feed only

WHAT WE KNOW

Oppenheimer initiated coverage of Amneal Pharmaceuticals (AMRX)
Rating: Outperform
Price target: $27